USV receives FDA close-out at Indian plant

By Staff Reporter

- Last updated on GMT


Related tags Food and drug administration Fda

The US FDA has lifted a warning at an Indian oral solid dose manufacturing facility run by USV Private Limited.

USV received a warning letter from the US Food and Drug Administration (FDA) last March​, following an inspection at its facility in Dabhel, Daman in 2016.

In the letter​, the FDA said USV’s “oversight and control over the manufacture of drugs is inadequate​,” citing problems over how the firm tested for microbial contamination at the site.

But now the Agency has given the facility the all clear in a close-out letter sent to USV last week.

“Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.”

According to USV, the Daman facility manufactures tablets, capsules and coated tablets and has certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Finnish Medicines Agency (Fimea), on top of the FDA.

The plant has 2,150 tonnes of granulation capacity and can produce 3.3bn tablets and 578m capsules.

Related news

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us


View more